Silver Lake Eyes Workday in One of the Biggest Software Takeovers Ever
Talks are ongoing as Workday shares fall amid AI concerns.
Already have an account? Sign in.
Talks are ongoing as Workday shares fall amid AI concerns.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.